Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/UQCRC2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/UQCRC2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/UQCRC2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/UQCRC2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/UQCRC2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/UQCRC2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/UQCRC2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/UQCRC2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/UQCRC2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0046034 | Colorectum | AD | ATP metabolic process | 142/3918 | 277/18723 | 2.64e-29 | 8.26e-26 | 142 |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0009060 | Colorectum | AD | aerobic respiration | 108/3918 | 189/18723 | 9.14e-28 | 1.43e-24 | 108 |
GO:0045333 | Colorectum | AD | cellular respiration | 119/3918 | 230/18723 | 3.21e-25 | 4.02e-22 | 119 |
GO:0006119 | Colorectum | AD | oxidative phosphorylation | 83/3918 | 141/18723 | 7.95e-23 | 8.30e-20 | 83 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0009410 | Colorectum | AD | response to xenobiotic stimulus | 128/3918 | 462/18723 | 2.69e-04 | 3.31e-03 | 128 |
GO:00090601 | Colorectum | SER | aerobic respiration | 96/2897 | 189/18723 | 5.53e-30 | 1.70e-26 | 96 |
GO:00460341 | Colorectum | SER | ATP metabolic process | 117/2897 | 277/18723 | 5.54e-27 | 1.13e-23 | 117 |
GO:00453331 | Colorectum | SER | cellular respiration | 103/2897 | 230/18723 | 2.35e-26 | 3.61e-23 | 103 |
GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
GO:00061191 | Colorectum | SER | oxidative phosphorylation | 75/2897 | 141/18723 | 2.35e-25 | 2.40e-22 | 75 |
GO:00159801 | Colorectum | SER | energy derivation by oxidation of organic compounds | 119/2897 | 318/18723 | 5.28e-22 | 4.62e-19 | 119 |
GO:00460344 | Colorectum | FAP | ATP metabolic process | 87/2622 | 277/18723 | 6.50e-14 | 6.63e-11 | 87 |
GO:00060914 | Colorectum | FAP | generation of precursor metabolites and energy | 128/2622 | 490/18723 | 5.58e-13 | 4.28e-10 | 128 |
GO:00159804 | Colorectum | FAP | energy derivation by oxidation of organic compounds | 85/2622 | 318/18723 | 1.36e-09 | 2.77e-07 | 85 |
GO:00090604 | Colorectum | FAP | aerobic respiration | 57/2622 | 189/18723 | 7.02e-09 | 1.02e-06 | 57 |
GO:00453334 | Colorectum | FAP | cellular respiration | 65/2622 | 230/18723 | 1.13e-08 | 1.33e-06 | 65 |
GO:00061194 | Colorectum | FAP | oxidative phosphorylation | 43/2622 | 141/18723 | 3.39e-07 | 1.86e-05 | 43 |
GO:00094102 | Colorectum | FAP | response to xenobiotic stimulus | 87/2622 | 462/18723 | 2.15e-03 | 1.77e-02 | 87 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501027 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
hsa0520829 | Prostate | Tumor | Chemical carcinogenesis - reactive oxygen species | 113/1791 | 223/8465 | 5.17e-23 | 1.90e-21 | 1.18e-21 | 113 |
hsa0501427 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
hsa0541528 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
hsa0493227 | Prostate | Tumor | Non-alcoholic fatty liver disease | 85/1791 | 155/8465 | 1.86e-20 | 5.14e-19 | 3.19e-19 | 85 |
hsa0471429 | Prostate | Tumor | Thermogenesis | 110/1791 | 232/8465 | 1.56e-19 | 3.96e-18 | 2.46e-18 | 110 |
hsa0502227 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
hsa0426025 | Prostate | Tumor | Cardiac muscle contraction | 28/1791 | 87/8465 | 1.06e-02 | 3.33e-02 | 2.07e-02 | 28 |
hsa0501237 | Prostate | Tumor | Parkinson disease | 144/1791 | 266/8465 | 3.33e-33 | 1.10e-30 | 6.83e-31 | 144 |
hsa0502036 | Prostate | Tumor | Prion disease | 142/1791 | 273/8465 | 2.80e-30 | 3.09e-28 | 1.92e-28 | 142 |
hsa0501636 | Prostate | Tumor | Huntington disease | 150/1791 | 306/8465 | 2.72e-28 | 2.25e-26 | 1.40e-26 | 150 |
hsa0019036 | Prostate | Tumor | Oxidative phosphorylation | 83/1791 | 134/8465 | 7.47e-25 | 4.12e-23 | 2.55e-23 | 83 |
hsa0501036 | Prostate | Tumor | Alzheimer disease | 166/1791 | 384/8465 | 1.64e-23 | 6.79e-22 | 4.21e-22 | 166 |
hsa0520837 | Prostate | Tumor | Chemical carcinogenesis - reactive oxygen species | 113/1791 | 223/8465 | 5.17e-23 | 1.90e-21 | 1.18e-21 | 113 |
hsa0501436 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
hsa0541536 | Prostate | Tumor | Diabetic cardiomyopathy | 103/1791 | 203/8465 | 4.04e-21 | 1.22e-19 | 7.54e-20 | 103 |
hsa0493236 | Prostate | Tumor | Non-alcoholic fatty liver disease | 85/1791 | 155/8465 | 1.86e-20 | 5.14e-19 | 3.19e-19 | 85 |
hsa0471437 | Prostate | Tumor | Thermogenesis | 110/1791 | 232/8465 | 1.56e-19 | 3.96e-18 | 2.46e-18 | 110 |
hsa0502236 | Prostate | Tumor | Pathways of neurodegeneration - multiple diseases | 182/1791 | 476/8465 | 1.34e-18 | 3.16e-17 | 1.96e-17 | 182 |
hsa0426034 | Prostate | Tumor | Cardiac muscle contraction | 28/1791 | 87/8465 | 1.06e-02 | 3.33e-02 | 2.07e-02 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UQCRC2 | SNV | Missense_Mutation | | c.757N>C | p.Tyr253His | p.Y253H | P22695 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UQCRC2 | SNV | Missense_Mutation | | c.964N>A | p.Asp322Asn | p.D322N | P22695 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
UQCRC2 | SNV | Missense_Mutation | | c.1287N>C | p.Lys429Asn | p.K429N | P22695 | protein_coding | tolerated(0.08) | benign(0.019) | TCGA-C8-A137-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
UQCRC2 | insertion | Nonsense_Mutation | novel | c.1191_1192insATTTACTTAAGAAAAACCTAAGT | p.Ser398IlefsTer7 | p.S398Ifs*7 | P22695 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
UQCRC2 | SNV | Missense_Mutation | | c.32N>T | p.Ser11Leu | p.S11L | P22695 | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
UQCRC2 | SNV | Missense_Mutation | novel | c.660N>C | p.Leu220Phe | p.L220F | P22695 | protein_coding | deleterious(0) | possibly_damaging(0.867) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
UQCRC2 | SNV | Missense_Mutation | | c.391G>A | p.Asp131Asn | p.D131N | P22695 | protein_coding | tolerated(0.06) | benign(0.02) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
UQCRC2 | SNV | Missense_Mutation | rs761498645 | c.91N>A | p.Ala31Thr | p.A31T | P22695 | protein_coding | tolerated(0.17) | benign(0.024) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
UQCRC2 | SNV | Missense_Mutation | novel | c.254N>C | p.Leu85Pro | p.L85P | P22695 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AA-3952-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
UQCRC2 | SNV | Missense_Mutation | | c.1057N>T | p.Ala353Ser | p.A353S | P22695 | protein_coding | tolerated(0.12) | benign(0.177) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |